The Falsified Medicines Directive (2011/62/EU) – (FMD) was transposed into UK law as The Human Medicines (Amendment) Regulations 2013 (SI 2013/1855) which came into force on 20 August 2013. Subsequent…
Read More
News Archive • Page 8 of 8 • Fortissa
Aspen is to pay £700m for GlaxoSmithKline’s off-patent blood clotting medicines; Arixtra and Fraxiparine including control of its factory in France. GSK will retain control of some markets in Asia…
European Commission publishes two new measures aimed at improving the safety of medical devices. The new rules are a Regulation strengthening the criterea to be met by notified bodies and…
Merck the US pharmaceutical manufacturer has announced a further 8500 job cuts in order to reduce annual operating costs by $2.5bn over the next two years. Merck intends to focus its…
Fortissa is proud to be involved with MOVEMBER this year with our Director’s and staff alike helping to raise funds for this good cause. During November of each year; Movember…
Due to difficulties at the manufacturing plant, production of BCG (ImmuCyst) has been suspended by the company Sanofi Pasteur. It has not, so far, been made clear what the production…
Our most recent audit by the Medicines and Healthcare Products Regulatory Agency (MHRA) was performed in July of 2012 and Fortissa was credited for its high quality standards, policies and…